Spero Therapeutics (SPRO) Net Margin (2016 - 2026)

Spero Therapeutics (SPRO) has reported Net Margin for 11 consecutive years, with 2791.47% the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, Net Margin fell 255540.0% year-over-year to 2791.47%; the trailing twelve-month figure through Jun 2026 stood at 12.33% (up 12268.0% YoY), and the FY2025 full-year result was 10.45%, up 15336.0% from the prior year.
• Net Margin slipped to 2791.47% in Q1 2026 per SPRO's latest filing, from 72.47% in the prior quarter.
• Across five years, Net Margin topped out at 72.47% in Q4 2025 and bottomed at 2791.47% in Q1 2026.
• Historically, Net Margin has averaged 469.92% across 5 years, with a median of 136.56% in 2024.
• The sharpest annual moves came in 2022 and 2026: Net Margin soared 105592 bps in 2022, then tumbled 255540 bps in 2026.
• Over 5 years, Net Margin stood at 56.43% in 2022, then climbed by 23 bps to 69.63% in 2023, then sank by 294 bps to 134.99% in 2024, then surged by 154 bps to 72.47% in 2025, then sank by 3952 bps to 2791.47% in 2026.
• According to Business Quant data, Net Margin over the past three periods registered 2791.47%, 72.47%, and 135.65% for Q1 2026, Q4 2025, and Q3 2025 respectively.